



Sandra Glucksmann Named 2009 Mass High Tech Woman to Watch

Cambridge MA – January 23, 2009 – Cerulean Pharma Inc., a biopharmaceutical company focused on novel, intelligently designed, nanoparticle-based drugs, today announced that Senior Vice President Sandra Glucksmann was named to its 2009 list of 10 “Women to Watch”. The newspaper will recognize achievements of 10 top women executives from New England technology companies.

The publication, working with an advisory panel drawn from some of the region’s leading academic and business institutions, selected the 2009 honorees, who exemplify the best and brightest among women at the highest level of technology businesses in New England.

The 10 women will be recognized in an evening gala at the Charles Hotel, One Bennett St., Cambridge, on Thursday, March 12, from 5:30 to 8:30 p.m. The women are being honored for their outstanding dedication to technology, entrepreneurship, lifelong learning and civic responsibility.

Prior to joining Cerulean, Sandra spent 13 years at Millennium Pharmaceuticals which she joined as one of its first scientists and where she held a series of positions with increasing responsibilities. Her division played an integral role in the numerous Millennium-large pharma collaborations, which generated over \$1.8 billion in funding for the company. Sandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago.

Sandra is committed to the helping women advance their careers and has played a very active role in mentoring technical women in the Boston community. She serves as Chair of the Board of Women Entrepreneurs in Science and Technology. She is also a member of Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics and serves on Board of Directors of Taconic Farms.

About Cerulean Pharma Inc.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Millennium Pharmaceuticals, Pfizer, GlaxoSmithKline, the Massachusetts Institute of Technology,

Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center. The company has been funded by leading investors Polaris Venture Partners, Venrock, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.ceruleanrx.com.

###